REFERENCES
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277–300.
- Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354 (1): 34–43.
- Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus in-travenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335 (26): 1950–5.
- Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus pa-clitaxel versus moderately high-dose carboplatin followed by intravenous pa-clitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, South-western Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19 (4): 1001–7.
- Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovar-ian carcinoma. Cancer 2000; 88 (1): 144–53.
- Gershenson DM, Kavanagh JJ, Copeland LI, Stringer CA, Morris M, Wharton JT. Re-treatment of patients with recurrent epithelial ovarian Cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989; 73 ( 5 Pt 1): 798-802.
- Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63 (1): 89–93.
- Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11 (12): 2405–10.
- Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Ver-weij J, Wanders J, et al. Docetaxel: an active new drug for treatment of ad-vanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87 (9): 676–81.
- Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16 (10): 3345–52.
- Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12 (1): 60–3.
- Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensi-tive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16 ( 2): 405-1O.
- Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in plat-inum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88 (1): 17–21.
- Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res 2004; 10 (9): 2962–7.
- Morgan RJ, Jr., Synold TW, Xi B, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2007;13 (4): 1232–7.
- Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemother-apy. A comparative pharmacokinetic analysis of platinum using a new math-ematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 2005; 99 (3): 591–6.